Top Drug Companies Agree to Joint Study for All-Oral Hep C Treatment
Vertex, Bristol-Myers Squibb partner on oral hepatitis C treatment
Saturday, April 6, 2013
By: Ira Kantor
Vertex Pharmaceuticals Inc. said today it has entered into a non-exclusive agreement with Bristol-Myers Squibb Company to conduct second, all-oral studies of the former’s VX-135 drug with the latter’s drug, daclatasvir, for the treatment of hepatitis C.
As part of the agreement, Vertex plans to conduct two of these studies of the combination, including an initial study in treatment-naive people with genotype 1 HCV infection planned for the second quarter of this year.
Continue reading this entire article: